• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期使用的眼药水的磷酸盐和渗透压水平评估

Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops.

作者信息

Özalp Onur, Atalay Eray, Alataş İbrahim Özkan, Küskü Kiraz Zeynep, Yıldırım Nilgün

机构信息

Eskişehir Osmangazi University Faculty of Medicine, Department of Ophthalmology, Eskişehir, Turkey

Eskişehir Osmangazi University Faculty of Medicine, Department of Medical Biochemistry, Eskişehir, Turkey

出版信息

Turk J Ophthalmol. 2019 Jun 27;49(3):123-129. doi: 10.4274/tjo.galenos.2018.43827.

DOI:10.4274/tjo.galenos.2018.43827
PMID:31245971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6624467/
Abstract

OBJECTIVES

To assess phosphate and osmolarity levels of chronically administered eye drops commercially available in Turkey.

MATERIALS AND METHODS

A total of 53 topical eye drops including 18 antiglaucoma drugs, 4 nonsteroidal anti-inflammatory drugs (NSAIDs), 10 corticosteroids, 7 antihistaminics, and 14 artificial tears identified using the Vademecum Modern Medications Guideline (2018) were included in the study. Phosphate levels were assessed using Roche Cobas C501 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) and the respective kits. Osmolarity was assessed using Vescor Vapro 5600 vapor pressure osmometer (Sanova Medical Systems, Vienna, Austria). Mean phosphate and osmolarity levels were obtained after averaging three measurements. Eye drops were categorized as isoosmolar, hypoosmolar and hyperosmolar based on physiologic tear osmolarity range (296.5±9.8 mOsm/L).

RESULTS

The highest phosphate concentration was found in the antiglaucoma group (20.3±35.4 mmol/L), followed by antihistaminics (17.3±17.9 mmol/L), corticosteroids (15.2±19.1 mmol/L), artificial tears (0.8±1.0), and NSAIDs (0.04±0.08). Percentage of medications in the hyperosmolar category was highest in the NSAI group (75%), followed by antihistaminics (43%), corticosteroids (20%), and antiglaucoma drugs (19%). Nearly all of the artificial tear formulations were in the hypoosmolar (71%) or isoosmolar (21%) categories.

CONCLUSION

Approximately 40% of glaucoma medications and approximately 60% of corticosteroid and antihistaminic medications had a phosphate concentration higher than the physiologic tear phosphate level (1.45 mmol/L).

摘要

目的

评估在土耳其可商购的长期使用的眼药水的磷酸盐和渗透压水平。

材料与方法

本研究纳入了总共53种局部用滴眼液,其中包括根据《现代药物指南(2018年)》确定的18种抗青光眼药物、4种非甾体抗炎药(NSAIDs)、10种皮质类固醇、7种抗组胺药和14种人工泪液。使用罗氏Cobas C501分析仪(德国曼海姆罗氏诊断有限公司)及相应试剂盒评估磷酸盐水平。使用Vescor Vapro 5600蒸气压渗透压计(奥地利维也纳Sanova医疗系统公司)评估渗透压。三次测量取平均值后得出平均磷酸盐和渗透压水平。根据生理泪液渗透压范围(296.5±9.8 mOsm/L),将眼药水分为等渗、低渗和高渗三类。

结果

抗青光眼组的磷酸盐浓度最高(20.3±35.4 mmol/L),其次是抗组胺药(17.3±17.9 mmol/L)、皮质类固醇(15.2±19.1 mmol/L)、人工泪液(0.8±1.0)和NSAIDs(0.04±0.08)。高渗类药物的比例在NSAI组中最高(75%),其次是抗组胺药(43%)、皮质类固醇(20%)和抗青光眼药物(19%)。几乎所有人工泪液制剂都属于低渗(71%)或等渗(21%)类别。

结论

约40%的青光眼药物以及约60%的皮质类固醇和抗组胺药物的磷酸盐浓度高于生理泪液磷酸盐水平(1.45 mmol/L)。

相似文献

1
Assessment of Phosphate and Osmolarity Levels in Chronically Administered Eye Drops.长期使用的眼药水的磷酸盐和渗透压水平评估
Turk J Ophthalmol. 2019 Jun 27;49(3):123-129. doi: 10.4274/tjo.galenos.2018.43827.
2
Osmolarity of prevalent eye drops, side effects, and therapeutic approaches.常见眼药水的渗透压、副作用及治疗方法。
Cornea. 2015 May;34(5):560-6. doi: 10.1097/ICO.0000000000000368.
3
Determination of phosphate concentration and pH in artificial tear drops.
Arch Soc Esp Oftalmol. 2016 Aug;91(8):372-8. doi: 10.1016/j.oftal.2016.01.018. Epub 2016 Feb 23.
4
Tear film osmolarity in patients treated for glaucoma or ocular hypertension.青光眼或高眼压症患者的泪膜渗透压。
Cornea. 2012 Sep;31(9):994-9. doi: 10.1097/ICO.0b013e31823f8cb6.
5
Effects of osmoprotective eye drops on tear osmolarity in contact lens wearers.渗透保护眼药水对隐形眼镜佩戴者泪液渗透压的影响。
Can J Ophthalmol. 2015 Aug;50(4):283-9. doi: 10.1016/j.jcjo.2015.03.008.
6
Determination of phosphate concentration in glaucoma eye drops commercially available in Spain.西班牙市售青光眼滴眼液中磷酸盐浓度的测定
Arch Soc Esp Oftalmol. 2016 Aug;91(8):363-71. doi: 10.1016/j.oftal.2016.02.010. Epub 2016 Mar 24.
7
In situ osmometry: validation and effect of sample collection technique.原位渗透压测定法:样本采集技术的验证及影响
Optom Vis Sci. 2013 Apr;90(4):359-65. doi: 10.1097/OPX.0b013e31828aaf10.
8
Tear osmolarity measurement using the TearLab Osmolarity System in the assessment of dry eye treatment effectiveness.使用 TearLab 渗透压系统测量泪液渗透压评估干眼治疗效果。
Cont Lens Anterior Eye. 2010 Apr;33(2):61-7. doi: 10.1016/j.clae.2010.01.003. Epub 2010 Feb 12.
9
Precision and accuracy of TearLab osmometer in measuring osmolarity of salt solutions.TearLab渗透压计测量盐溶液渗透压的精密度和准确度。
Curr Eye Res. 2014 Dec;39(12):1247-50. doi: 10.3109/02713683.2014.906623. Epub 2014 Apr 18.
10
Short-term changes in tear osmolarity after instillation of different osmolarity eye drops in patients with dry eye.干眼症患者滴用不同渗透压滴眼液后泪液渗透压的短期变化。
Sci Rep. 2023 Jul 7;13(1):11012. doi: 10.1038/s41598-023-35965-0.

引用本文的文献

1
The new preservative-free ophthalmic formulation of bilastine 0.6% preserves the ocular surface epithelial integrity in a comparative in vitro study.一项比较性的体外研究表明,新型无防腐剂苯海拉明滴眼液(0.6%)可维持眼表面上皮细胞的完整性。
Sci Rep. 2024 Apr 26;14(1):9598. doi: 10.1038/s41598-024-59190-5.
2
Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence.创新单剂量系统包装的透明质酸中胱胺滴眼液:稳定性和眼内生物持久性
Pharmaceutics. 2022 Oct 15;14(10):2194. doi: 10.3390/pharmaceutics14102194.
3
Cyclodextrins Allow the Combination of Incompatible Vancomycin and Ceftazidime into an Ophthalmic Formulation for the Treatment of Bacterial Keratitis.

本文引用的文献

1
Short break-up time type dry eye has potential ocular surface abnormalities.短泪膜破裂时间型干眼存在潜在的眼表异常。
Taiwan J Ophthalmol. 2015 Apr-Jun;5(2):68-71. doi: 10.1016/j.tjo.2015.02.004. Epub 2015 May 4.
2
TFOS DEWS II Report Executive Summary.TFOS DEWS II 报告执行摘要。
Ocul Surf. 2017 Oct;15(4):802-812. doi: 10.1016/j.jtos.2017.08.003. Epub 2017 Aug 8.
3
TFOS DEWS II Tear Film Report.TFOS DEWS II 泪膜报告。
环糊精可将不兼容的万古霉素和头孢他啶组合成一种眼科配方,用于治疗细菌性角膜炎。
Int J Mol Sci. 2021 Sep 29;22(19):10538. doi: 10.3390/ijms221910538.
Ocul Surf. 2017 Jul;15(3):366-403. doi: 10.1016/j.jtos.2017.03.006. Epub 2017 Jul 20.
4
Determination of phosphate concentration in glaucoma eye drops commercially available in Spain.西班牙市售青光眼滴眼液中磷酸盐浓度的测定
Arch Soc Esp Oftalmol. 2016 Aug;91(8):363-71. doi: 10.1016/j.oftal.2016.02.010. Epub 2016 Mar 24.
5
Osmolarity of prevalent eye drops, side effects, and therapeutic approaches.常见眼药水的渗透压、副作用及治疗方法。
Cornea. 2015 May;34(5):560-6. doi: 10.1097/ICO.0000000000000368.
6
Corneal calcification and phosphates: do you need to prescribe phosphate free?角膜钙化与磷酸盐:是否需要开具无磷酸盐处方?
J Ocul Pharmacol Ther. 2014 Dec;30(10):800-2. doi: 10.1089/jop.2014.0054.
7
Evaluation of allergic conjunctivitis by thermography.通过热成像技术评估过敏性结膜炎
Ophthalmic Res. 2014;51(3):161-6. doi: 10.1159/000357105. Epub 2014 Mar 5.
8
Changing the composition of buffered eye-drops prevents undesired side effects.改变缓冲眼药水的成分可预防不良的副作用。
Br J Ophthalmol. 2010 Nov;94(11):1519-22. doi: 10.1136/bjo.2009.177386. Epub 2010 Jul 21.
9
Performance of tear osmolarity compared to previous diagnostic tests for dry eye diseases.泪液渗透压与其他干眼病诊断测试的性能比较。
Curr Eye Res. 2010 Jul;35(7):553-64. doi: 10.3109/02713683.2010.484557.
10
Effect of hypotonic 0.4% hyaluronic acid drops in dry eye patients: a cross-over study.低渗0.4%透明质酸滴眼液对干眼患者的影响:一项交叉研究。
Cornea. 2008 Dec;27(10):1126-30. doi: 10.1097/ICO.0b013e318180e55c.